VULTAGGIO, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 5.716
EU - Europa 4.119
AS - Asia 975
OC - Oceania 60
AF - Africa 26
SA - Sud America 3
Totale 10.899
Nazione #
US - Stati Uniti d'America 5.699
RU - Federazione Russa 1.435
PL - Polonia 1.118
IT - Italia 427
SE - Svezia 392
IE - Irlanda 369
SG - Singapore 305
HK - Hong Kong 236
CN - Cina 183
FI - Finlandia 97
JO - Giordania 86
DE - Germania 78
GB - Regno Unito 78
UA - Ucraina 63
IN - India 60
AU - Australia 59
TR - Turchia 38
ID - Indonesia 35
VN - Vietnam 25
CH - Svizzera 23
BE - Belgio 18
CI - Costa d'Avorio 18
CA - Canada 17
FR - Francia 11
NG - Nigeria 3
NL - Olanda 3
SC - Seychelles 3
BR - Brasile 2
ES - Italia 2
IR - Iran 2
LV - Lettonia 2
AR - Argentina 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GE - Georgia 1
KR - Corea 1
LK - Sri Lanka 1
LT - Lituania 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
RO - Romania 1
TH - Thailandia 1
TW - Taiwan 1
Totale 10.899
Città #
Santa Clara 1.491
Warsaw 1.118
Fairfield 584
Chandler 445
Dublin 369
Ashburn 349
Singapore 253
Cambridge 239
Seattle 227
Woodbridge 223
Houston 219
Wilmington 216
Hong Kong 150
Ann Arbor 144
Jacksonville 118
Lawrence 118
Altamura 116
Princeton 96
Florence 88
Beijing 70
Buffalo 68
Moscow 67
Boardman 65
Melbourne 59
Boston 57
Mumbai 54
Shanghai 53
Medford 45
New York 42
San Diego 38
Izmir 35
Jakarta 33
Los Angeles 31
Helsinki 27
Kent 25
Dong Ket 24
Luni 22
Norwalk 20
Abidjan 18
Bern 17
Brussels 17
Falls Church 17
Milan 16
London 14
Washington 14
Yubileyny 13
Salerno 11
Andover 10
Toronto 10
Bremen 9
Phoenix 8
Liverpool 7
Livorno 7
Naples 6
Tappahannock 6
Frankfurt am Main 5
Laurel 5
Ottawa 5
Redwood City 5
Rome 5
Castelliri 4
Hillsboro 4
Lappeenranta 4
Munich 4
Nanchang 4
Auburn Hills 3
Busto Arsizio 3
Campi Bisenzio 3
Caulonia 3
Paris 3
Ponti sul Mincio 3
Redmond 3
San Mateo 3
Sesto Fiorentino 3
Acton 2
Ankara 2
Arnsberg 2
Barcelona 2
Bologna 2
Chicago 2
Dongguan 2
Duncan 2
Frankfurt Am Main 2
Fuzhou 2
Genoa 2
Imola 2
Lambeth 2
Latina 2
Leawood 2
Milzano 2
Monopoli 2
Nola 2
Old Bridge 2
Palermo 2
Parma 2
Pesaro 2
Pomigliano d'Arco 2
Prescot 2
Pune 2
Riga 2
Totale 7.722
Nome #
Treatment with 8-OH-modified adenine (TLR7 ligand)-allergen conjugates decreases T helper type 2-oriented murine airway inflammation 289
A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy 278
Hapten-Specific TH17 Cells in the Peripheral Blood of β-Lactam-Induced AGEP. 270
Dermatophagoides pteronyssinus group 2 allergen bound to 8-OH modified adenine reduces the Th2-mediated airway inflammation without inducing a Th17 response and autoimmunity 250
Potential underestimation of risks in hazelnuts-allergic patients: a peculiar case report 217
The in vitro amplification of β-lactam-specific memory t cells improves the diagnostic performance of IGE detection and lymphocyte transformation test 201
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies 178
Efficacy and safety of mepolizumab (Anti-Interleukin-5) treatment in Gleich's syndrome 165
Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study 164
T cells specific for Candida albicans antigens and producing type 2 cytokines in lesional mucosa of untreated HIV-infected patients with pseudomembranous oropharyngeal candidiasis. 163
High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics 163
Biweekly hizentra® in primary immunodeficiency: A multicenter, observational cohort study (IBIS) 160
The TLR7 Ligand 9-Benzyl-2-Butoxy-8-Hydroxy Adenine Inhibits IL-17 Response by Eliciting IL-10 and IL-10-Inducing Cytokines. 159
Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. 150
Assays and strategies for immunogenicity assessment of biological agents. 134
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 134
Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. 133
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab 132
Detection by flow cytometry of ESAT-6- and PPD-specific circulating CD4+ T lymphocytes as a diagnostic tool for tuberculosis. 130
Miescher's cheilitis: Surgical management and long term outcome of an extremely severe case. 130
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study 128
Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42] 127
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 125
Microchimerism and systemic sclerosis 123
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. 118
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. 116
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI 116
Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study 116
A novel allergen-adjuvant conjugate suitable for allergen-specific Th2 redirection 114
Vav1 haploinsufficiency in a common variable immunodeficiency patient with defective T-cell function. 114
Redirection of allergen-specific Th2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release 113
Defective production of LIF, M-CSF and Th2-type cytokines by T cells at fetomaternal interface is associated with pregnancy loss. 112
The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment 112
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab 111
Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. 110
Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. 109
PS1-076. Redirection of allergen-specific TH2 cells by a modified adenine chemically coupled to allergenic molecule(s) 106
High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients 104
Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies 104
Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. 100
Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. 100
T cells specific for Candida albicans antigens and producing type 2 cytokines in lesional mucosa of untreated HIV-infected patients with pseudomembranous oropharyngeal candidiasis 100
Apten-specific proliferation as diagnostic tool in drug hypersensitivity. 99
Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19 99
Total serum IgE levels influence the in vitro detection of ss-lactams-specific IgE antibodies 98
Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis 96
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study 95
Coronary vasospasm during an acute allergic reaction 94
A novel nDer p2-conjugated TLR7 down-modulates Th2-associated lung inflammation by using a therapeutical protocol 94
A modified adenine chemically coupled to allergenic molecule(s) as inducer of allergen-specific Th2 cells redirection 93
Association between "sarcoidosis-like" disease and common variable immunodeficiency (CVI): a new CVI variant showing an activation of the immune system. 91
Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity 91
A modified adenine chemically coupled to the allergen molecule of Dermatophagoides pteronyssinus redirects allergen-specific Th2 cells 91
Poly(I:C) promotes the production of IL-17A by murine CD1d-driven invariant NKT cells in airway inflammation. 90
T-cell responses during allergen-specific immunotherapy. 89
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 88
"Sarcoidosis-like" granulomatous disease in patients with common variable hypogammaglobulinemia 87
Type 1 T helper cells specific for Candida albicans antigens in peripheral blood and vaginal mucosa of women with recurrent vaginal candidiasis. 87
A modified adenines chemically coupled to allergen molecule of dermatophagoides pteronyssinus down-regulates allergen-specific Th2 cells responses 85
Can SSRI/SNRI antidepressants decrease the 'cytokine storm' in the course of COVID-19 pneumonia? 85
Immediate adverse reactions to biologicals:from pathogenic mechanisms to prophylactic management 84
Hydroxy-adenines as in vivo and in vitro immunomodulators of allergic responses 83
Multiorgan Infiltration by CD8+ T Cells and 1p;16p Translocation in a Patient with Hypogammaglobulinemia and a Reduced Number of B Cells. 83
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 82
A modified adenine chemically coupled to allergen molecole redirects allergen-specific Th2 cells 81
Asthma:developments in targeted therapy. 81
Lack of efficacy of Cyclosporine A in a patient with episodic angioedema and eosinophilia (Gleich's syndrome) 81
Influence of total serum IgE levels on the in vitro detection of beta-lactams-specific IgE antibodies. 80
Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma 80
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 78
Modified adenines chemically coupled to allergen molecule induce interferon-gamma production and down-regulate IL-4 and IL-5 in Th2-specific T cells 78
Short and long-term effect of a novel nDer p2-conjugated TLR7 ligand in the prevention of allergic lung inflammation 78
A modified adenine chemically coupled to allergen molecule(s) induce Interferon-gamma production and down regulate IL-4 and IL-5 in Th2 specific T cells 76
A modified adenines chemically coupled to allergenic molecule(s) as inducerof allergen-specific Th2 cells redirection 76
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 74
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 73
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 72
Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: a two-year real-life experience 72
Tako-Tsubo-like syndrome during anaphylactic reaction. 71
Highly active antiretroviral therapy including inhibitory proteases in HIV-infected patients induces a restored T cell-mediated immune response to C. albicans antigens and Th1 profile [abstract]. 70
Partial safety of the new COX2-inhibitor refecoxib in NSAIDs high sensitive patients 68
A novel antigen-conjugated TLR7 ligand regulates the lung inflammation and Th2-mediated response in a murine model of asthma 68
Regulation of fetal allograft survival by hormone-controlled T cell cytokines 68
Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab 66
Tako-Tsubo-like syndrome during anaphylactic reaction. 66
Asthma: developments in targeted therapy. 66
Immunogenicity of Biological Agents: Basic Knowledge and Clinical Implications 64
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study 61
Heart as the early maintarget of severe anaphylactic reactions: two case reports 60
Acute infusion reactions induced bymonoclonal antibody therapy 59
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience 57
Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis 57
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis 56
Polyomavirus JC detection in patients with rheumatic disease after a long-term treatment with infliximab. 55
The management of paediatric allergy: not everybody's cup of tea--10-11th February 2012. 55
Modified (2-Butoxy-8-Hydroxy-9-Benzyl) adenine redirects type 2 murine lung inflammation by triggering TLR7 in dendritic cells 54
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study 53
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 53
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 52
Primary antibody deficiencies represent an underestimated comorbidity in asthma patients: efficacy of immunoglobulin replacement therapy in asthma control 51
Totale 10.472
Categoria #
all - tutte 33.153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.153


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020740 0 0 0 0 0 0 156 182 140 113 128 21
2020/20211.023 94 85 41 133 50 131 39 67 105 142 71 65
2021/2022657 20 60 45 19 23 36 33 59 25 32 134 171
2022/20231.843 150 367 92 148 133 313 231 98 218 14 45 34
2023/2024873 36 71 106 60 80 110 59 166 17 54 71 43
2024/20253.846 187 546 310 856 1.390 557 0 0 0 0 0 0
Totale 10.996